Trial Profile
Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Oxybutynin; Tolterodine
- Indications Detrusor instability
- Focus Therapeutic Use
- 10 Apr 2023 Status changed from recruiting to completed.
- 22 Aug 2014 New trial record